
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you open and fund a new account within 30 days
- Access to a financial planner
Alkermes is a drug manufacturers - specialty & generic business based in the US. Alkermes shares (ALKS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $31.78 – an increase of 14.15% over the previous week. Alkermes employs 1,800 staff and has a trailing 12-month revenue of around $1.6 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Latest market close | $31.78 |
---|---|
52-week range | $22.90 - $36.45 |
50-day moving average | $32.09 |
200-day moving average | $29.41 |
Wall St. target price | $39.36 |
PE ratio | 13.0773 |
Dividend yield | N/A |
Earnings per share (TTM) | $2.20 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $31.78 from 2025-05-02
1 week (2025-04-23) | 17.05% |
---|---|
1 month (2025-04-04) | 5.72% |
3 months (2025-02-04) | 1.53% |
6 months (2024-11-04) | 19.52% |
1 year (2024-05-03) | 32.14% |
---|---|
2 years (2023-05-03) | 10.92% |
3 years (2022-05-03) | 9.59% |
5 years (2020-05-04) | 131.30% |
Valuing Alkermes stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alkermes's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alkermes's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Alkermes shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Alkermes's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $449.2 million.
The EBITDA is a measure of a Alkermes's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $1.6 billion |
---|---|
Operating margin TTM | 37.84% |
Gross profit TTM | $1.3 billion |
Return on assets TTM | 12.54% |
Return on equity TTM | 27.9% |
Profit margin | 23.57% |
Book value | $9.03 |
Market Capitalization | $4.7 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Alkermes.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.83
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Alkermes's overall score of 28.83 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Alkermes is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.37/100
Alkermes's environmental score of 0.37 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Alkermes is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 17.49/100
Alkermes's social score of 17.49 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Alkermes is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 8.71/100
Alkermes's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Alkermes is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Alkermes scored a 1 out of 5 for controversy – the highest score possible, reflecting that Alkermes has managed to keep its nose clean.
Alkermes Plc was last rated for ESG on: 2019-01-01.
Total ESG score | 28.83 |
---|---|
Total ESG percentile | 53.12 |
Environmental score | 0.37 |
Environmental score percentile | 1 |
Social score | 17.49 |
Social score percentile | 1 |
Governance score | 8.71 |
Governance score percentile | 1 |
Level of controversy | 1 |
We're not expecting Alkermes to pay a dividend over the next 12 months.
Alkermes's shares were split on a 2:1 basis on 14 May 2000 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Alkermes shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Alkermes shares which in turn could have impacted Alkermes's share price.
Over the last 12 months, Alkermes's shares have ranged in value from as little as $22.9 up to $36.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alkermes's is 0.348. This would suggest that Alkermes's shares are less volatile than average (for this exchange).
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N. V. , Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.